FDA cleared the Single-use Balloon Dilatation Catheter (AG-5251-083018 AG-5251-085518 AG-5251-088018 AG-5251-083019 AG-5251-085519 AG-5251-088019 AG-5251-083021 AG-5251-085521 AG-5251-088021 AG-5251-083024 AG-5251-085524 AG-5251-088024 AG-5251-103018 AG-5251-105518 AG-5251-108018 AG-5251-103019 AG-5251-105519 AG-5251-108019 AG-5251-103021 AG-5251-105521 AG-5251-108021 AG-5251-103024 AG-5251-105524 AG-5251-108024 AG-5251-123018 AG-5251-125518 AG-5251-128018 AG-5251-123019 AG-5251-125519 AG-5251-128019 from Hangzhou AGS MedTech Co., Ltd. on Jun 24, 2026 under K253393, a traditional 510(k). The device falls under product code FGE, Stents, Drains And Dilators For The Biliary Ducts, regulated at 21 CFR 876.5010 as a Class 2 device. The review panel was Gastroenterology, Urology.
FDA logged the submission as received on Sep 30, 2025. The decision came 267 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.
Hangzhou AGS MedTech Co., Ltd. has 3 other decisions in the tracker over the last 12 months: K254069 (Hemoclip (511 series, 543 series)), K252270 (Hemoclip), K252271 (Hemoclip).
Questions & Answers
What did FDA clear under K253393?
K253393 is the FDA 510(k) for Single-use Balloon Dilatation Catheter (AG-5251-083018 AG-5251-085518 AG-5251-088018 AG-5251-083019 AG-5251-085519 AG-5251-088019 AG-5251-083021 AG-5251-085521 AG-5251-088021 AG-5251-083024 AG-5251-085524 AG-5251-088024 AG-5251-103018 AG-5251-105518 AG-5251-108018 AG-5251-103019 AG-5251-105519 AG-5251-108019 AG-5251-103021 AG-5251-105521 AG-5251-108021 AG-5251-103024 AG-5251-105524 AG-5251-108024 AG-5251-123018 AG-5251-125518 AG-5251-128018 AG-5251-123019 AG-5251-125519 AG-5251-128019, submitted by Hangzhou AGS MedTech Co., Ltd.. FDA's decision date was Jun 24, 2026, under product code FGE (Stents, Drains And Dilators For The Biliary Ducts).
Who makes the Single-use Balloon Dilatation Catheter (AG-5251-083018 AG-5251-085518 AG-5251-088018 AG-5251-083019 AG-5251-085519 AG-5251-088019 AG-5251-083021 AG-5251-085521 AG-5251-088021 AG-5251-083024 AG-5251-085524 AG-5251-088024 AG-5251-103018 AG-5251-105518 AG-5251-108018 AG-5251-103019 AG-5251-105519 AG-5251-108019 AG-5251-103021 AG-5251-105521 AG-5251-108021 AG-5251-103024 AG-5251-105524 AG-5251-108024 AG-5251-123018 AG-5251-125518 AG-5251-128018 AG-5251-123019 AG-5251-125519 AG-5251-128019?
Hangzhou AGS MedTech Co., Ltd., based in Hangzhou, is the applicant of record for K253393.
How long did the K253393 review take?
FDA received the submission on Sep 30, 2025 and issued its decision on Jun 24, 2026, 267 days later.